Gene Therapy for Hemophilia B Using CRISPR/Cas9
Author Information
Author(s): Lara-Navarro Irving Jair, Jave-Suárez Luis Felipe, Marchal Juan Antonio, Jaloma-Cruz Ana Rebeca
Primary Institution: Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara
Hypothesis
Can CRISPR/Cas9 be used to effectively edit the F9 gene in human mesenchymal stem cells for hemophilia B therapy?
Conclusion
The study demonstrates successful gene editing and expression of clotting factor IX in human mesenchymal stem cells using the CRISPR/Cas9 system.
Supporting Evidence
- Successful gene editing was achieved in both cell models.
- F9 expression was confirmed through quantitative analysis.
- Editing efficiency was found to be lower in human mesenchymal stem cells.
Takeaway
Scientists are trying to fix a problem in the genes of people with hemophilia B using a tool called CRISPR, which helps make the body produce a special protein that stops bleeding.
Methodology
The study involved using CRISPR/Cas9 to edit the F9 gene in human mesenchymal stem cells and Lenti-X HEK293 cells, followed by validation of gene expression and protein production.
Limitations
Editing efficiency was lower in human mesenchymal stem cells compared to Lenti-X HEK293 cells.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website